AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO)
Transcript of AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO)
AMERICAN SOCIETY OF CLINICAL ONCOLOGY(ASCO)
ASCO21 Virtual Scientific Program
June 4-8, 2021eCompendium
Copies of files obtained through links contained in this compendium are for personal use only and may not be reproduced without permission from ASCO® and the author of the presentation. This compilation of QR codes is intended as an educational resource and is for the exchange of scientific data to clinical investigators and health care professionals.
Copyright © 2021 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved.
PEMBROLIZUMAB
RCC
BELZUTIFAN(MK-6482)
Colorectal
PEMBROLIZUMAB + LENVATINIB
Gastric Melanoma RCC
Lung
PEMBROLIZUMAB + OLAPARIB
FAVEZELIMAB(MK-4280)
Colorectal
Gynecologic Hepatobiliary Translational
Hepatobiliary
LENVATINIB
Melanoma Lung Bladder RCC
Prostate Gynecologic Head and Neck GI/Gastric
Colorectal Hepatobiliary Across Tumor Types
Breast
TUCATINIB
Solid Tumor
Neurofibromatosis
SELUMETINIBOLAPARIB
Ovarian
Prostate
3
Melanoma
Title/Author
Presentation
Type
Date and Time
EDT
Download
Presentation
Download
Poster Slides
Crossover and rechallenge with pembrolizumab in recurrent patients from the
EORTC 1325-mg/KEYNOTE-054 phase 3 trial, pembrolizumab vs placebo after
complete resection of high-risk stage III melanoma
Eggermont AMM, Meshcheryakov A, Atkinson V, Blank CU, Mandala M, Long GV,
Barrow C, Di Giacomo AM, Fisher R, Sandhu S, Kudchadkar R, Ortiz Romero PL, Svane IM,
van Akkooi A, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suciu S, Robert C
Oral
Presentation
Sunday
June 6, 2021
8:00-11:00 AM ▼
KEYNOTE-555 Cohort B: Efficacy, safety, and pharmacokinetics of pembrolizumab
400 mg every 6 weeks as first-line therapy for advanced melanoma
Jacobs C, Rapoport B, Chan SW, Ruff P, Arance Fernandez A, Eizmendi KM, Anderson JR,
Lala M, Jain L, Akala O, Chartash E, Cohen G
Poster
Friday
June 4, 2021
9:00 AM ▼ ▼
PEMBROLIZUMAB
4
Lung
Title/Author
Presentation
Type
Date and Time
EDT
Download
Presentation
Download
Poster Slides
KEYNOTE-799: Phase 2 trial of pembrolizumab plus platinum chemotherapy and
radiotherapy for unresectable, locally advanced, stage III NSCLC
Jabbour SK, Lee KH, Frost N, Breder V, Kowalski DM, Alawin I, Levchenko E, Reguart N,
Martinez-Marti A, Houghton B, Paoli J-B, Safina S, Park K, Komiya T, Sanford A, Boolell V,
Liu H, Samkari A, Keller SM, Reck M
Poster
Discussion
Friday
June 4, 2021
8:00-11:00 AM ▼ ▼Health-related quality of life for pembrolizumab + ipilimumab vs pembrolizumab +
placebo in patients with metastatic NSCLC with PD-L1 tumor proportion score ≥50%:
KEYNOTE-598
Şendur MAN, Reck M, Rodríguez-Abreu D, Park K, Lee DH, Cicin I, Yumuk PF, Orlandi FJ,
Leal TA, Molinier O, Soparattanapaisarn N, Langleben A, Califano R, Medgyasszay B,
Hsia T-C, Otterson G, Xu L, Burke T, Samkari A, Boyer M
Poster
Friday
June 4, 2021
9:00 AM ▼ ▼
PEMBROLIZUMAB
5
Bladder
Title/Author
Presentation
Type
Date and Time
EDT
Download
Presentation
Download
Poster Slides
First-line pembrolizumab in cisplatin-ineligible patients with advanced urothelial
cancer: Response and survival results up to 5 years from the KEYNOTE-052
phase 2 study
O’Donnell PH, Balar AV, Vuky J, Castellano DE, Bellmunt J, Powles T, Bajorin DF, Grivas P,
Hahn NM, Plimack ER, Xu JZ, Godwin JL, Homet Moreno B, de Wit R
Oral
Presentation
Monday
June 7, 2021
8:00-11:00 AM ▼Pembrolizumab vs investigator’s choice of paclitaxel, docetaxel, or vinflunine
in recurrent, advanced urothelial cancer: 5-year follow-up from the phase 3
KEYNOTE-045 trial
Bellmunt J, Necchi N, de Wit R, Lee J-L, Fong L, Vogelzang NJ, Climent MA, Petrylak DP,
Choueiri TK, Gerritsen WR, Gurney H, Quinn DI, Culine S, Sternberg CN, Xu J,
Homet Moreno B, Godwin JL, Bajorin DF, Vaughn DJ, Fradet Y
Poster
Friday
June 4, 2021
9:00 AM ▼ ▼KEYNOTE-B15/EV-304: A phase 3, randomized, open-label study of perioperative
enfortumab vedotin plus pembrolizumab vs chemotherapy in cisplatin-eligible patients
with muscle-invasive bladder cancer
Hoimes C, Bedke J, Loriot Y, Nishiyama H, Fang X, Kataria RS, Homet Moreno B,
Galsky MD
Poster
Friday
June 4, 2021
9:00 AM ▼ ▼
PEMBROLIZUMAB
6
RCC
Title/Author
Presentation
Type
Date and Time
EDT
Download
Presentation
Download
Poster Slides
Pembrolizumab plus axitinib vs sunitinib as first-line therapy for advanced clear cell
renal cell carcinoma: Results from 42-month follow-up of KEYNOTE-426
Rini BI, Plimack ER, Stus V, Waddell T, Gafanov R, Pouliot F, Nosov D, Melichar B,
Soulières D, Borchiellini D, Vynnychenko I, McDermott RS, Azevedo SJ, Tamada S,
Kryzhanivska A, Li C, Burgents JE, Molife LR, Bedke J, Powles T
Oral
Presentation
Monday
June 7, 2021
8:00-11:00 AM ▼A phase 1b/2 umbrella study of investigational immune and targeted combination
therapies as first-line therapy for patients with advanced renal cell carcinoma
(Substudy03A)
Plimack ER, Hammers HJ, Choueiri TK, Rini BI, Motzer RJ, Suttner L, Perini RF,
Willemann-Rogerio J, Albiges L
Poster
Friday
June 4, 2021
9:00 AM ▼ ▼
PEMBROLIZUMAB
7
RCC
Title/Author
Presentation
Type
Date and Time
EDT
Download
Presentation
Download
Poster Slides
Pembrolizumab vs placebo as post-nephrectomy adjuvant therapy for patients with
renal cell carcinoma: Randomized, double-blind, phase 3 KEYNOTE-564 study
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang Y-H, Hajek J,
Symeonides S, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas N,
Sawrycki P, Perini RF, Zhang P, Willemann-Rogerio J, Imai K, Quinn D, Powles T, on
behalf of the KEYNOTE-564 investigators
Plenary
Session
Sunday
June 6, 2021
1:00 PM ▼Disease-free survival as a predictor of overall survival in localized renal cell carcinoma
(RCC) following initial nephrectomy
Haas NB, Song Y, Willemann Rogerio J, Zhang S, Adejoro O, Carley C, Zhu J,
Bhattacharya R, Signorovitch J, Sundaram M
Poster
Friday
June 4, 2021
9:00 AM ▼ ▼
PEMBROLIZUMAB
8
Prostate
Title/Author
Presentation
Type
Date and Time
EDT
Download
Presentation
Download
Poster Slides
Pembrolizumab plus enzalutamide for enzalutamide-resistant, metastatic
castration-resistant prostate cancer: Updated analyses after one additional
year of follow-up from cohorts 4 and 5 of the KEYNOTE-199 study
Graff JN, Tagawa ST, Hoimes CJ, Gerritsen WR, Vaishampayan UN, Elliott T,
Hwang C, Ten Tije AJ, Omlin A, McDermott RS, Fradet Y, Kilari D, Ferrario C,
Uemura H, Niu C, Poehlein CH, de Wit R, Schloss C, de Bono JS, Antonarakis ES
Poster
Friday
June 4, 2021
9:00 AM ▼ ▼
PEMBROLIZUMAB
9
Gynecologic
Title/Author
Presentation
Type
Date and Time
EDT
Download
Presentation
Download
Poster Slides
ENGOT-en11/GOG-3053/KEYNOTE-B21: Phase 3 study of pembrolizumab or placebo
in combination with adjuvant chemotherapy with/without radiotherapy in patients
with newly diagnosed high-risk endometrial cancer
Van Gorp T, Mirza MR, Lortholary A, Cibula D, Walther A, Savarese A,
Barretina-Ginesta M-P, Ortaç F, Papadimitriou C, Bodnar L, Lai C-H, Korach J, Marth C,
Hasegawa K, Xie X, Barber EL, Coleman RL, Keefe S, Orlowski R, Slomovitz B
Poster
Friday
June 4, 2021
9:00 AM ▼ ▼
PEMBROLIZUMAB
10
Head and Neck
Title/Author
Presentation
Type
Date and Time
EDT
Download
Presentation
Download
Poster Slides
KEYNOTE-629: Health-related quality of life with pembrolizumab in patients with
locally advanced or recurrent or metastatic cutaneous squamous cell carcinoma
Bratland Å, Munoz-Couselo E, Mortier L, Roshdy O, González R, Schachter J, Arance AM,
Grange F, Meyer N, Joshi AJ, Billan S, Hughes BGM, Grob JJ, Ramakrishnan K, Zhang P,
Gumuscu B, Swaby RF, Gutzmer R
Poster
Friday
June 4, 2021
9:00 AM ▼ ▼
PEMBROLIZUMAB
11
GI/Gastric
Title/Author
Presentation
Type
Date and Time
EDT
Download
Presentation
Download
Poster Slides
First-line pembrolizumab plus chemotherapy vs chemotherapy in patients with
advanced esophageal cancer: Chinese subgroup analysis of KEYNOTE-590
Li Z, Sun Y, Ye F, Ma D, Yin X, Zhuang W, Yuan X, Qin S, Zhang Y, Gu K, Zhao K, Xiao J,
Cheng Y, Bai Y, Luo S, Wang L, Wang C, Cui Y, Mei L, Shen L
Poster
Friday
June 4, 2021
9:00 AM ▼ ▼Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic
gastric or gastroesophageal junction cancer: Initial findings of the global phase 3
KEYNOTE-811 study
Janjigian YY, Kawazoe A, Yañez P, Luo S, Lonardi S, Kolesnik O, Barajas O, Bai Y,
Shen L, Tang Y, Wyrwicz LS, Shitara K, Qin S, Van Cutsem E, Tabernero J, Li L,
Shih C-S, Bhagia P, Chung HC, on behalf of the KEYNOTE-811 investigators
Poster
Discussion
Friday
June 4, 2021
9:00-10:00 AM ▼
PEMBROLIZUMAB
12
Colorectal
Title/Author
Presentation
Type
Date and Time
EDT
Download
Presentation
Download
Poster Slides
Final overall survival for the phase 3 KN177 study: Pembrolizumab vs chemotherapy in
microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic
colorectal cancer (mCRC)
André T, Shiu K-K, Kim TW, Jensen BV, Jensen LH, Punt C, Smith D, Garcia-Carbonero R,
Alcaide-Garcia J, Gibbs P, de la Fouchardiere C, Rivera F, Elez E, Bendell J, Le DT,
Yoshino T, Zhong W, Fogelman D, Marinello P, Diaz Jr LA
Oral
Presentation
Monday
June 7, 2021
1:15-4:15 PM ▼
PEMBROLIZUMAB
13
Hepatobiliary
Title/Author
Presentation
Type
Date and Time
EDT
Download
Presentation
Download
Poster Slides
Pembrolizumab monotherapy for previously untreated advanced hepatocellular
carcinoma: Phase 2 KEYNOTE-224 study
Van Laethem JL, Borbath I, Karwal M, Verslype C, Van Vlierberghe H, Kardosh A,
Zagonel V, Stal P, Sarker D, Palmer D, Vogel A, Edeline J, Cattan S, Kudo M, Cheng AL,
Ogasawara S, Siegel AB, Chisamore M, Wang A, Zhu AX
Poster
Friday
June 4, 2021
9:00 AM ▼Pembrolizumab (pembro) vs placebo (pbo) in patients (pts) with advanced
hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from
the randomized, phase 3 KEYNOTE-240 study
Finn RS, Edeline J, Bouattour M, Cheng AL, Chan SL, Yau T, Garrido M, Knox J, Daniele B,
Zhu AX, Breder V, Lim HY, Ogasawara S, Siegel AB, Rahman A, Wei Z, Merle P
Poster
Friday
June 4, 2021
9:00 AM ▼
PEMBROLIZUMAB
14
Across Tumor Types
Title/Author
Presentation
Type
Date and Time
EDT
Download
Presentation
Download
Poster Slides
Pembrolizumab in microsatellite instability high/mismatch repair–deficient cancers:
Updated analysis from phase 2 KEYNOTE-158 study
Maio M, Ascierto PA, Manzyuk L, Motola-Kuba D, Penel N, Cassier PA,
Mendonca Bariani G, De Jesus Acosta A, Doi T, Longo Muñoz F, Miller Jr WH,
Oh D-Y, Gottfried M, Wang R, Jin F, Norwood K, Marabelle A
Poster
Friday
June 4, 2021
9:00 AM ▼A comprehensive literature review and meta-analysis on prevalence of BRCAm,
HRRm, and HRD+ across tumor types
Shao C, Wan J, Tang H, Marley A, Miller C, Brown M, Song Y, Han J, Adeboyege G
Poster
Friday
June 4, 2021
9:00 AM ▼A comprehensive literature review and meta-analysis on prognostic value of BRCAm,
HRRm, and HRD+ across tumor types
Shao C, Marley A, Tang H, Wan J, Miller C, Brown M, Song Y, Han J, Adeboyeje G
Poster
Friday
June 4, 2021
9:00 AM ▼Pembrolizumab patient-reported benefits: A perspective based on multiple tumors
Wu E, Miskala PH, Siddiqui MK, Rai P, Hajdukova E, Erpelding N, Vanderpuye-Orgle J Poster
Friday
June 4, 2021
9:00 AM ▼
PEMBROLIZUMAB
15
CRC
Title/Author
Presentation
Type
Date and Time
EDT
Download
Presentation
Download
Poster Slides
LEAP-005: A phase 2 multicohort study of lenvatinib plus pembrolizumab in patients
with previously treated selected solid tumors: Results from the colorectal cancer cohort
Gomez-Roca C, Yanez E, Im S-A, Castanon E, Senellart H, Doherty M, Garcia Corbacho J,
Lopez J, Basu B, Maurice-Dror C, Gill S, Ghori R, Kubiak P, Jin F, Norwood K, Chung HC
Poster
Friday
June 4, 2021
9:00 AM ▼
PEMBROLIZUMAB + LENVATINIB
16
Colorectal
Title/Author
Presentation
Type
Date and Time
EDT
Download
Presentation
Download
Poster Slides
LEAP-005: A phase 2 multicohort study of lenvatinib plus pembrolizumab in
patients with previously treated selected solid tumors: Results from the gastric
cancer cohort
Chung HC, Lwin Z, Gomez-Roca C, Longo Muñoz F, Yanez E, Castanon E, Graham DM,
Doherty M, Cassier P, Lopez J, Basu B, Hendifar AE, Maurice-Dror C, Gill S, Ghori R,
Kubiak P, Jin F, Norwood K, Saada-Bouzid E
Poster
Friday
June 4, 2021
9:00 AM ▼
PEMBROLIZUMAB + LENVATINIB
17
Hepatobiliary
Title/Author
Presentation
Type
Date and Time
EDT
Download
Presentation
Download
Poster Slides
Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers
in the multicohort phase 2 LEAP-005 study
Villanueva L, Lwin Z, Chung HC, Gomez-Roca C, Longo Muñoz F, Yanez E, Senellart H,
Doherty M, Garcia-Corbacho J, Hendifar AE, Maurice-Dror C, Gill S, Kim TW, Heudobler D,
Penel N, Ghori R, Kubiak P, Jin F, Norwood K, Graham DM
Poster
Friday
June 4, 2021
9:00 AM ▼
PEMBROLIZUMAB + LENVATINIB
18
Melanoma
Title/Author
Presentation
Type
Date and Time
EDT
Download
Presentation
Download
Poster Slides
Lenvatinib plus pembrolizumab for patients with advanced melanoma and confirmed
progression on a PD-1 or PD-L1 inhibitor: Updated findings of LEAP-004
Arance A, de la Cruz Merino L, Petrella TM, Jamal R, Ny L, Carneiro A, Berrocal A,
Marquez-Rodas I, Spreafico A, Atkinson V, Costa Svedman F, Mant A, Smith AD, Chen K,
Diede SJ, Krepler C, Long GV
Oral
Presentation
Sunday
June 6, 2021
8:00-11:00 AM ▼
PEMBROLIZUMAB + LENVATINIB
19
RCC
Title/Author
Presentation
Type
Date and Time
EDT
Download
Presentation
Download
Poster Slides
Health‐related quality‐of‐life analysis from the phase 3 CLEAR trial of lenvatinib plus
pembrolizumab or everolimus vs sunitinib for patients with advanced renal cell
carcinoma
Motzer R, Porta C, Alekseev B, Young Rha S, Choueiri T, Mendez-Vidal MJ, Hong S-H,
Kapoor A, Goh JC, Eto M, Wang J, Pan J, Asfaw AA, He CS, Mody K, Cella D
Oral
Presentation
Monday
June 7, 2021
8:00-11:00 AM ▼KEYNOTE-B61: Open-label phase 2 study of pembrolizumab in combination with
lenvatinib as first-line treatment for non–clear cell renal carcinoma
Lee C-H, Li C, Perini RF, Hoehn D, Albiges L
Poster
Friday
June 4, 2021
9:00 AM ▼ ▼
PEMBROLIZUMAB + LENVATINIB
20
RCC
Title/Author
Presentation
Type
Date and Time
EDT
Download
Presentation
Download
Poster Slides
Analysis of the CLEAR study in patients with advanced renal cell carcinoma: depth of
response and efficacy for selected subgroups in the lenvatinib-plus-pembrolizumab and
sunitinib treatment arms
Grunwald V, Powles T, Kopyltsov E, Kozlov V, Alonso Gordoa TA, Eto M, Hutson T,
Motzer R, Winquist E, Maroto P, Keam B, Procopio G, Wong S, Melichar B, Rolland F,
Oya M, Rodriguez-Lopez K, Saito K, Smith A, Porta C
Poster
Friday
June 4, 2021
9:00 AM ▼Post hoc analysis of the CLEAR study in advanced renal cell carcinoma: effect of
subsequent therapy on survival outcomes in the lenvatinib + everolimus versus
sunitinib treatment arms
Hutson T, Choueiri TK, Motzer R, Young Rha S, Alyasova A, Merchan J, Gurney H, Peer A,
Takagi T, Porta C, Powles T, Grunwald V, De Giorgi U, Vaishampayan U, Schmidinger M,
Glen H, Rodriguez-Lopez K, Xing D, Dutta L, Eto M
Poster
Friday
June 4, 2021
9:00 AM ▼
PEMBROLIZUMAB + LENVATINIB
21
Gynecologic
Title/Author
Presentation
Type
Date and Time
EDT
Download
Presentation
Download
Poster Slides
Health-related quality of life in advanced endometrial cancer patients treated with
lenvatinib + pembrolizumab or treatment of physician’s choice
Lorusso D, Colombo N, Casado Herraez A, Santin A, Colomba E, Miller DS,
Fujiwara K, Pignata S, Baron-Hay SE, Ray-Coquard IL, Shapira-Frommer R, Man Kim Y,
McCormack M, Bird S, Prabhu VS, Nguyen AM, Zhao Q, Dutta L, Makker V
Poster
Friday
June 4, 2021
9:00 AM ▼ ▼Treatment patterns and outcomes among patients with microsatellite stable (MSS)
advanced endometrial cancer who progressed following previous systemic therapy in
the United States: Endometrial cancer health outcomes (ECHO) retrospective chart
review study
Corman S, Kelkar SS, Odak S, Zhang J, Prabhu VS, Rusibamayila N, Macahilig C, Duska L
Poster
Friday
June 4, 2021
9:00 AM ▼
PEMBROLIZUMAB + LENVATINIB
22
Translational
Title/Author
Presentation
Type
Date and Time
EDT
Download
Presentation
Download
Poster Slides
Exploratory circulating biomarker analyses: Lenvatinib + pembrolizumab (L + P) in a
phase 1b trial in unresectable hepatocellular carcinoma (uHCC)
Zhu AX, Llovet JM, Kobayashi M, Ikeda M, Pracht M, Sung MW, Baron AD, Kudo M,
Meyer T, Okusaka T, Kumada H, Kaneko S, Hoshi T, Saito K, Li SD, Funahashi Y,
Minoshima Y, Dubrovsky L, Finn RS
Poster
Friday
June 4, 2021
9:00 AM ▼ ▼
PEMBROLIZUMAB + LENVATINIB
23
RCC
Title/Author
Presentation
Type
Date and Time
EDT
Download
Presentation
Download
Poster Slides
Phase 2 study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2α inhibitor,
for Von Hippel-Lindau disease–associated clear cell renal cell carcinoma
Srinivasan R, Donskov F, Iliopoulos O, Rathmell WK, Narayan V, Maughan BL, Oudard S,
Else T, Maranchie JK, Welsh SJ, Roy A, Liu Y, Perini RF, Linehan WM, Jonasch E
Poster
Friday
June 4, 2021
9:00 AM ▼ ▼
BELZUTIFAN (MK-6482)
24
Lung
Title/Author
Presentation
Type
Date and Time
EDT
Download
Presentation
Download
Poster Slides
Phase 3 study of pembrolizumab with concurrent chemoradiation therapy followed
by pembrolizumab with or without olaparib vs concurrent chemoradiation therapy
followed by durvalumab in unresectable, locally advanced, stage III non-small-cell
lung cancer: KEYLYNK-012
Jabbour SK, Cho BC, Bria E, Kato T, Bhosle J, Gainor JF, Reguart N, Wang L,
Morgensztern D, Gurary EB, Ashraf TB, Lara-Guerra H, Reck M
Poster
Friday
June 4, 2021
9:00 AM ▼KEYLYNK-013: A phase 3 study of pembrolizumab in combination with concurrent
chemoradiation therapy followed by pembrolizumab with or without olaparib vs
concurrent chemoradiation therapy in patients with newly diagnosed limited-
stage SCLC
Rimner A, Lai V, Califano R, Jabbour SK, Faivre-Finn C, Cho BC, Kato T, Yu J, Yu L,
Zhao B, Pietanza MC, Byers L
Poster
Friday
June 4, 2021
9:00 AM ▼
PEMBROLIZUMAB + OLAPARIB
25
Colorectal
Title/Author
Presentation
Type
Date and Time
EDT
Download
Presentation
Download
Poster Slides
A phase 1 first-in-human study of the anti-LAG-3 antibody MK-4280 (favezelimab)
plus pembrolizumab in previously treated, advanced microsatellite stable
colorectal cancer
Garralda E, Sukari A, Lakhani NJ, Patnaik A, Lou Y, Im S-A, Golan T, Geva R, Wermke M,
de Miguel M, Palcza J, Jha S, Chaney M, Healy J, Falchook GS
Poster
Friday
June 4, 2021
9:00 AM ▼ ▼
FAVEZELIMAB (MK-4280)
26
Hepatobiliary
Title/Author
Presentation
Type
Date and Time
EDT
Download
Presentation
Download
Poster Slides
The cost effectiveness of first line lenvatinib versus atezolizumab and bevacizumab or
sorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in Canada
Trueman D, Liu Y, Geadah M, Hon N, Sabapathy S, Kamboj L, Li H, Lucero M, Meier G
Poster
Friday
June 4, 2021
9:00 AM ▼ ▼
LENVATINIB
27
Prostate
Title/Author
Presentation
Type
Date and Time
EDT
Download
Presentation
Download
Poster Slides
Indirect treatment comparison of the efficacy of olaparib 300 mg tablets BID and
cabazitaxel 25 mg/m2 every 3 weeks plus daily prednisolone and granulocyte
colony-stimulating factor in the treatment of patients with metastatic
castration-resistant prostate cancer
Reason T, McCrea C, Hettle R, Ghate S, Poehlein C, Olmos D
Poster
Friday
June 4, 2021
9:00 AM ▼
OLAPARIB
28
Ovarian
Title/Author
Presentation
Type
Date and Time
EDT
Download
Presentation
Download
Poster Slides
EFFORT: Efficacy of adavosertib in PARP resistance: A randomized 2-arm
non-comparative phase II study of adavosertib with or without olaparib in women
with PARP-resistant ovarian cancer
Westin SN, Coleman RL, Fellman B, Yuan Y, Sood A, Soliman P, Wright A, Horowitz N,
Campos S, Konstantinopoulos P, Levenback C, Gershenson D, Lu K, Bayer V, Tukdi S,
Rabbit A, Ottesen L, Godin R, Mills G, Li JF
Oral
Presentation
Monday
June 7, 2021
8:00-11:00 AM ▼Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated
(non-gBRCAm) platinum-sensitive relapsed ovarian cancer patients: Phase IIIb
OPINION primary analysis
Poveda A, Lheureux S, Colombo N, Cibula D, Lindemann K, Weberpals J, Bjurberg M,
Oaknin A, Sikorska M, González-Martín A, Madry R, Rubio Pérez M, Ledermann J,
Davidson R, Blakeley C, Bennett J, Brown J, Škof E
Poster
Friday
June 4, 2021
9:00 AM ▼Olaparib treatment in patients with platinum-sensitive relapsed ovarian cancer by
BRCA mutation and homologous recombination deficiency status: Overall survival
results from the phase II LIGHT study
Mathews C, Simpkins F, Cadoo K, Liu Y, Provencher D, McCormick C, EINaggar AC,
Altman AD, Gilbert L, Black D, Kabil N, Bennett J, Munley J, Yu H, Aghajanian C
Poster
Discussion
Friday
June 4, 2021
9:00 AM ▼
OLAPARIB
29
Breast
Title/Author
Presentation
Type
Date and Time
EDT
Download
Presentation
Download
Poster Slides
HER2CLIMB-04: Phase 2 open label trial of tucatinib + trastuzumab deruxtecan in
patients with HER2+ unresectable locally advanced or metastatic breast cancer with
and without brain metastases (trial in progress)
Krop I, Ramos J, Zhang C, Hamilton E
Poster
Friday
June 4, 2021
9:00 AM ▼ ▼Alliance A011801 (CompassHER2 RD): Postneoadjuvant T-DM1 + tucatinib/placebo in
patients with residual HER2-positive invasive breast cancer
O'Sullivan CC, Ballman KV, McCall L, Zemla T, Weiss A, Mitchell M, Blinder V, Tung NM,
Irvin MJ, Lee M, Goetz MP, Symmans WF, Borges VF, Krop I, Partridge AH, Carey LA
Poster
Friday
June 4, 2021
9:00 AM ▼
TUCATINIB
30
Breast
Title/Author
Presentation
Type
Date and Time
EDT
Download
Presentation
Download
Poster Slides
Updated results of tucatinib vs placebo added to trastuzumab and capecitabine for
patients with pretreated HER2+metastatic breast cancer with and without brain
metastases (HER2CLIMB)
Curigliano G, Mueller V, Borges V, Hamilton E, Hurvitz S, Loi S, Murthy R, Okines A,
Paplomata E, Cameron D, Carey L, Gelmon K, Hortobagyi G, Krop I, Loibl S, Pegram M,
Slamon D, Ramos J, Zhang C, Winer E
Poster
Friday
June 4, 2021
9:00 AM ▼ ▼Pharmacokinetic (PK) analyses in CSF and plasma from TBCRC049, an ongoing trial to
assess the safety and efficacy of the combination of tucatinib, trastuzumab, and
capecitabine for the treatment of leptomeningeal metastasis (LM) in HER2 positive
breast cancer
Stringer-Reasor EM, O'Brien BJ, Topletz-Erickson A, White J, Lobbous M, Riley K,
Childress J, Lamaster K, Melisko M, Morikawa A, de Groot JF, Krop I, Valero V, Rimawi M,
Wolff A, Tripathy D, Lin NU, Murthy RK
Poster
Friday
June 4, 2021
9:00 AM ▼
TUCATINIB
31
Solid Tumor
Title/Author
Presentation
Type
Date and Time
EDT
Download
Presentation
Download
Poster Slides
SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated
solid tumors with HER2 alterations (trial in progress)
Stinchcombe T, Monk BJ, Okines AFC, Pohlmann PR, Yu EY, Bekaii-Saab TS, Nakamura Y,
O'Malley DM, Kang V, Walker LN, Reck M
Poster
Friday
June 4, 2021
9:00 AM ▼ ▼
TUCATINIB
32
Neurofibromatosis
Title/Author
Presentation
Type
Date and Time
EDT
Download
Presentation
Download
Poster Slides
Health-related quality of life (HRQoL) among pediatric patients with neurofibromatosis
type 1 (NF1) and plexiform neurofibroma (PN) in the United States (US)
Yang X, Yoo HK, Amin S, Cheng WY, Sipsma H, Sundaresan S, Zhang L, Duh MS
Poster
Friday
June 4, 2021
9:00 AM ▼
SELUMETINIB